Articles

Men whose activity exceeded guideline-based exercise levels experienced a decreased likelihood of lower serum testosterone, according to study results presented at the American Urological Association 2020 Virtual Experience.

Exceeding exercise guidelines may reduce likelihood of low T in men

The FDA recently granted approval for Jelmyto, which is the first therapy for the treatment of low-grade upper tract urothelial cancer. Urology Times® spoke with Angela B. Smith, MD, MS, regarding the significance of this approval for providers and patients.

Dr. Angela Smith discusses the recent FDA approval of Jelmyto for low-grade UTUC

Misinformation about prostate cancer is rampant online and significantly impacts patient care, study authors said at an American Urological Association press briefing. Researchers using machine learning have taken what they say is a first step to help vet the quality of online content.

Online prostate cancer videos earn poor grade for accuracy

Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.

Findings from a study characterizing the providers and services offered by stand-alone commercialized men’s health clinics should be eye-opening and alarming for urologists, said Jagan K. Kansal, MD, MBA, at the American Urological Association 2020 Virtual Experience.

Marketing used by men’s health clinics is cause for concern

The benefits of minimally invasive water vapor thermal therapy (Rezūm System) on lower urinary tract symptoms due to benign prostatic hyperplasia are durable, with a reduction in symptom score and an improvement in flow rate sustained to 5 years, according to researchers.

Water vapor thermal therapy results found durable at 5 years

Data from a large registry showed that active surveillance for small renal masses was safe and noninferior to primary intervention at 10 years. In this video, senior author Phillip M. Pierorazio, MD, of Johns Hopkins University discusses results of the study presented as part of the AUA 2020 Virtual Experience.

Surveillance for small renal masses appears safe at 10 years

Disease progression within 6 months was the strongest surrogate marker for overall survival in patients with metastatic hormone-sensitive prostate cancer treated with combination therapy in a retrospective analysis of the CHAARTED trial.

6-month progression is strong survival surrogate in mHSPC

Analyses of data from a multi-institutional registry show that blue light cystoscopy using hexaminolevulinate HCl (Cysview) detects invasive bladder tumors that are missed by white light cystoscopy in an appreciable number of patients.

Blue light cystoscopy enables earlier detection of invasive bladder tumors

Women with mixed urinary incontinence seeking surgical intervention for refractory urinary urge incontinence have the same low risk of subsequently needing surgery for stress urinary incontinence whether they are treated with intradetrusor onabotulinumtoxinA (BTX [Botox]) injections or sacral neuromodulation.

Mixed incontinence patients show low risk for needing SUI surgery

In this video, Seth P. Lerner, MD, discusses the OLYMPUS Trial of intracavitary UGN-101 (mitomycin gel; Jelmyto) in patients with low-grade upper tract urothelial carcinoma.

UTUC therapy yields high rate of disease eradication, durability

Compared with local radiation therapy, radical prostatectomy as primary treatment for prostate cancer may result in a lower risk of castration-resistant disease and superior overall survival from the time of metastasis.

RP leads to better survival vs radiation from time of metastasis

“UGN-101… has the potential to change practice for patients with low-grade renal pelvis cancer,” says researcher John L. Gore, MD.

UTUC agent linked to high rate of disease eradication

Researchers found that 30 of 46 study participants (65%) experienced more than a 50% improvement in urgency urinary incontinence with the nickel-sized device.

OAB device produces durable efficacy at 12 months

Increasing the frequency setting on a holmium:YAG laser increases stone fragmentation, but determining the saturation point at which efficiency plateaus requires further study.

Laser lithotripsy: Is there a saturation point for frequency?

The majority of medication prescribed to patients undergoing outpatient urologic procedures goes unused, prospective data reveal.

Post-procedure opioid Rx may be unnecessary

An analysis of Medicare expenditures in the first year after a diagnosis of prostate cancer shows that 5% of patients account for almost 25% of the total spending.

What drives costs of prostate cancer care?

The use of enzalutamide (XTANDI) and abiraterone acetate (ZYTIGA) show differences in overall survival and health care costs when used to treat chemotherapy-naïve metastatic castrate-resistant prostate cancer.

Enzalutamide vs. abiraterone: Survival, care costs compared

With the AUA annual meeting quickly approaching, Victor W. Nitti, MD, chair of the AUA Office of Education, provides a snapshot of new course offerings and other AUA educational opportunities.

Dr. Nitti: 32 new courses on tap at AUA 2019

In advance of this year’s AUA annual meeting, Urology Times asked members of our editorial board to choose the top presentations in their subspecialty.

AUA 2019: Experts outline the must-see presentations in Chicago

Urologist Ray Painter, MD, is president of Physician Reimbursement Systems, Inc., in Denver, and is also publisher of Urology Coding and Reimbursement Sourcebook.

Mark Painter is CEO of PRS Urology SC in Denver.

Ray Painter, MD, and Mark Painter also answer coding questions regarding vasectomy and code 50543.